125 related articles for article (PubMed ID: 36995150)
1. Audiologic Follow-up in Patients With Head and Neck Cancer Treated With Cisplatin and Radiation.
Lee DS; Travis EY; Wong SK; Collopy C; McClannahan KS; Ortmann AJ; Rich JT; Pipkorn P; Puram SV; Jackson RS; Paniello RC; Adkins DR; Oppelt P; Thorstad WL; Wick CC; Zevallos JP; Mazul AL
Laryngoscope; 2023 Nov; 133(11):3161-3168. PubMed ID: 36995150
[TBL] [Abstract][Full Text] [Related]
2. Trends in ototoxicity monitoring among cisplatin-treated patients with cancer.
Lee DS; Travis EY; Wong SK; Munyemana MA; Mueller L; Rowling CC; Rich JT; Pipkorn P; Puram SV; Jackson RS; Adkins DR; Oppelt P; Thorstad WL; Wick CC; Zevallos JP; McClannahan K; Mazul AL
J Cancer Surviv; 2024 Apr; ():. PubMed ID: 38630333
[TBL] [Abstract][Full Text] [Related]
3. Insight into the current practice of ototoxicity monitoring during cisplatin therapy.
Santucci NM; Garber B; Ivory R; Kuhn MA; Stephen M; Aizenberg D
J Otolaryngol Head Neck Surg; 2021 Mar; 50(1):19. PubMed ID: 33766142
[TBL] [Abstract][Full Text] [Related]
4. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer.
Madasu R; Ruckenstein MJ; Leake F; Steere E; Robbins KT
Arch Otolaryngol Head Neck Surg; 1997 Sep; 123(9):978-81. PubMed ID: 9305250
[TBL] [Abstract][Full Text] [Related]
5. Hearing evaluation of patients with head and neck cancer: Comparison of Common Terminology Criteria for Adverse Events, Brock and Chang adverse event criteria in patients receiving cisplatin.
Colevas AD; Lira RR; Colevas EA; Lavori PW; Chan C; Shultz DB; Chang KW
Head Neck; 2015 Aug; 37(8):1102-7. PubMed ID: 24737682
[TBL] [Abstract][Full Text] [Related]
6. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
7. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Rasch CR; Schornagel JH; Dreschler WA; Balm AJ
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1320-5. PubMed ID: 17418969
[TBL] [Abstract][Full Text] [Related]
8. High prevalence of cisplatin-induced ototoxicity in Cape Town, South Africa.
Whitehorn H; Sibanda M; Lacerda M; Spracklen T; Ramma L; Dalvie S; Ramesar R
S Afr Med J; 2014 Apr; 104(4):288-91. PubMed ID: 25118554
[TBL] [Abstract][Full Text] [Related]
9. The Relationship Between Cisplatin-related and Age-related Hearing Loss During an Extended Follow-up.
Skalleberg J; Småstuen MC; Oldenburg J; Osnes T; Fosså SD; Bunne M
Laryngoscope; 2020 Sep; 130(9):E515-E521. PubMed ID: 32065408
[TBL] [Abstract][Full Text] [Related]
10. Validation of Hearing Loss Prediction Tool for Cisplatin Chemotherapy and Radiation in Head and Neck Cancer Treatment.
Deutsch BC; Collopy C; Kallogjeri D; Piccirillo JF
JAMA Otolaryngol Head Neck Surg; 2021 Feb; 147(2):182-189. PubMed ID: 33300954
[TBL] [Abstract][Full Text] [Related]
11. Ototoxicity and long-term hearing outcome in pediatric patients receiving cisplatin.
Sriyapai T; Thongyai K; Phuakpet K; Vathana N; Buaboonnam J; Sanpakit K
Turk J Pediatr; 2022; 64(3):531-541. PubMed ID: 35899566
[TBL] [Abstract][Full Text] [Related]
12. [Ototoxicity in head and neck cancers after radiotherapy and chemoradiotherapy: From primary prevention to tertiary prevention].
Espenel S; Garcia MA; Guy JB; Vallard A; Ben Mrad M; Langrand-Escure J; El Meddeb Hamrouni A; Trone JC; Xia Y; Rancoule C; Magné N
Cancer Radiother; 2017 Feb; 21(1):77-83. PubMed ID: 28189351
[TBL] [Abstract][Full Text] [Related]
13. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
14. Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.
Bass JK; Huang J; Onar-Thomas A; Chang KW; Bhagat SP; Chintagumpala M; Bartels U; Gururangan S; Hassall T; Heath JA; McCowage G; Cohn RJ; Fisher MJ; Robinson G; Broniscer A; Gajjar A; Gurney JG
Pediatr Blood Cancer; 2014 Apr; 61(4):601-5. PubMed ID: 24504791
[TBL] [Abstract][Full Text] [Related]
15. Predicting Hearing Loss After Radiotherapy and Cisplatin Chemotherapy in Patients With Head and Neck Cancer.
Schuette A; Lander DP; Kallogjeri D; Collopy C; Goddu S; Wildes TM; Daly M; Piccirillo JF
JAMA Otolaryngol Head Neck Surg; 2020 Feb; 146(2):106-112. PubMed ID: 31750863
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer.
Rolland V; Meyer F; Guitton MJ; Bussières R; Philippon D; Bairati I; Leclerc M; Côté M
J Otolaryngol Head Neck Surg; 2019 Jan; 48(1):4. PubMed ID: 30651130
[TBL] [Abstract][Full Text] [Related]
17. Hearing and tinnitus in head and neck cancer patients after chemoradiotherapy.
Niemensivu R; Saarilahti K; Ylikoski J; Aarnisalo A; Mäkitie AA
Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2509-14. PubMed ID: 26685859
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a cisplatin dose-ototoxicity model.
Dille MF; Wilmington D; McMillan GP; Helt W; Fausti SA; Konrad-Martin D
J Am Acad Audiol; 2012; 23(7):510-21. PubMed ID: 22992258
[TBL] [Abstract][Full Text] [Related]
19. Effect of cisplatin on distortion product otoacoustic emissions in Japanese patients.
Eiamprapai P; Yamamoto N; Hiraumi H; Ogino-Nishimura E; Kitamura M; Hirano S; Ito J
Laryngoscope; 2012 Jun; 122(6):1392-6. PubMed ID: 22555987
[TBL] [Abstract][Full Text] [Related]
20. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.
Bokemeyer C; Berger CC; Hartmann JT; Kollmannsberger C; Schmoll HJ; Kuczyk MA; Kanz L
Br J Cancer; 1998 Apr; 77(8):1355-62. PubMed ID: 9579846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
